Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 12/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26969729 | 0.91 | NPY5R (0.40) | NPY5RACLYNOTUMALDH1A1TSHR | |
| SCHEMBL30733438 | 0.82 | NPY5R (0.44) | NPY5RACLYNOTUMALDH1A1TSHR | |
| SCHEMBL30733413 | 0.81 | TACR1 (0.46) | NPY5RACLYNOTUMALDH1A1TSHR | |
| SCHEMBL30733400 | 0.77 | NPY5R (0.44) | NPY5RACLYNOTUMALDH1A1TSHR | |
| SCHEMBL30733443 | 0.76 | TACR1 (0.45) | NPY5RACLYNOTUMALDH1A1TSHR | |
| SCHEMBL30733430 | 0.76 | TSHR (0.49) | NPY5RACLYNOTUMALDH1A1TSHR | |
| SCHEMBL26969719 | 0.75 | TSHR (0.48) | NPY5RACLYNOTUMALDH1A1TSHR | |
| SCHEMBL30733405 | 0.74 | TSHR (0.50) | ACLYNOTUMALDH1A1TSHR | |
| SCHEMBL26969746 | 0.74 | TACR1 (0.45) | NPY5RACLYTACR1 | |
| SCHEMBL30733423 | 0.73 | KCNN4 (0.47) | ACLYNOTUMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | NPY5R 681/4885ACLY 3265/4885NOTUM 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.